Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.

[1]  J. Douillard,et al.  Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment , 2011, British Journal of Cancer.

[2]  C. Bokemeyer,et al.  Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  E. Van Cutsem,et al.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Peeters,et al.  Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab , 2010, International Journal of Colorectal Disease.

[5]  M. Stockler,et al.  Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Bokemeyer,et al.  Patients and Methods: the European Organisation for Research and Treatment of Cancer Qol Questionnaire , 2022 .

[7]  R. Pearson,et al.  Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer , 2010 .

[8]  Linda Mol,et al.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.

[9]  Murielle Mauer,et al.  Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. , 2009, The Lancet. Oncology.

[10]  N. Pavlakis,et al.  Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Bokemeyer,et al.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[13]  D. Cella,et al.  Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. , 2008, The oncologist.

[14]  W. Scheithauer,et al.  EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Park,et al.  Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy , 2008, Quality of Life Research.

[16]  E. Van Cutsem,et al.  Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab , 2007, British Journal of Cancer.

[17]  K. Ang,et al.  Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Van Steen,et al.  Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? , 2006, European journal of cancer.

[19]  A. Bottomley,et al.  Toward a clearer understanding of the prognostic value of health-related quality-of-life parameters in breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Brenner,et al.  Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Norman,et al.  Baseline quality of life predicts survival in patients with advanced colorectal cancer. , 2002, European journal of cancer.

[22]  R. Gelber,et al.  Quality of life scores predict outcome in metastatic but not in early breast cancer , 2001 .

[23]  R. Gelber,et al.  Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Geert Molenberghs,et al.  Linear Mixed Models in Practice , 1997 .

[25]  Andrew Bottomley,et al.  EORTC QLQ-C30 Scoring Manual , 1995 .

[26]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .